CBRM unveils catalogue of pre-approved housing designs to help spark development
CBRM unveiled the 15 different plans, called fast-tracked housing designs, on Monday in front of city hall.
Spokesperson Jenna MacQueen said there was lots of public interest in the plans, which were paid for as part of an $11.4-million grant from the federal Housing Accelerator Fund.
"Some people are very excited. Some people are saying, 'I can't believe this hasn't happened sooner.' There's some people that are even from different municipalities that are looking to build here because they were shocked that this was being done here," she said.
MacQueen said the plans are pre-approved for building permits because they meet building code requirements and were created in consultation with CBRM staff and home builders.
That could shave six months or more off the permitting process, she said.
'Reducing housing barriers'
Many of the 15 designs will fit on an average-sized lot in CBRM, but they range from a 435-square-foot backyard suite to a six-unit multiplex, MacQueen said.
"What we're doing is making sure that we're reducing barriers to make sure that people can build housing here in the CBRM," she said.
More than half of the federal housing grant has been dedicated to Cape Breton University's Tartan Downs housing project and the Cossitt Heights subdivision that's already being built by Joneljim Construction.
The rest is paying for a new online permitting system, grants for the development of new affordable housing units, a parking study, staff housing co-ordinator and an overall housing strategy.
MacQueen said the Housing Accelerator Fund, which is administered by the Canada Mortgage and Housing Corporation, also supports tax breaks for affordable housing, but CBRM has decided to forego the tax revenue on its own in order to direct the federal funds to the other initiatives.
The fast-tracked housing designs are available on CBRM's website.
MORE TOP STORIES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a significant milestone by reporting positive EBITDA for the first time in its history, indicating a path towards profitability. The company reported a 21% increase in revenue for the first quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of its technology. Biotricity Inc (BTCY) has expanded its cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's Tensorflow, enhancing diagnostic accuracy and patient outcomes. The company has secured regulatory approvals in multiple international markets, including Canada, Saudi Arabia, and Argentina, aligning with its strategy for global expansion. Gross profit for the quarter increased by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%, reflecting operational efficiencies and a strong recurring revenue base. Negative Points Despite improvements, Biotricity Inc (BTCY) reported a net loss of $754,000 for the first quarter, although this was a significant improvement from the prior year's loss. The company faces challenges with rising variable interest rates, which could impact future financial performance. Biotricity Inc (BTCY) is still in the process of pursuing FDA clearance for its AI clinical model, which could delay the full commercialization of its new technologies. Operating expenses, although reduced, remain a concern as the company continues to invest in R&D and sales force transformation. The company's expansion into new verticals and international markets may require significant resources and could face regulatory and competitive challenges. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with BTCY. Q: Can you provide more details on the strategic partnerships mentioned in the call? A: Dr. Walkus Al Sadiq, CEO, highlighted that Biotricity has formed strategic partnerships with industry giants like Amazon AWS and Google's Tensorflow to expand their cardiac AI cloud platform. These partnerships are crucial for enhancing diagnostic accuracy and improving patient outcomes. Additionally, alliances with three major group purchasing organizations (GPOs) in the US provide access to approximately 90% of hospitals, significantly expanding market access. Q: What are the financial highlights for the first quarter of fiscal 2026? A: Johnny Abo, CFO, reported a 21% increase in revenue to $3.9 million compared to the previous year. Gross profit rose by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%. Operating expenses decreased by 18.5%, and the company achieved a positive EBITDA of $333,000, marking the first quarter of positive EBITDA in Biotricity's history. Q: How is Biotricity addressing the market for atrial fibrillation monitoring? A: The CFO emphasized that atrial fibrillation, a major contributor to strokes, remains a significant focus. Biotricity's technology has monitored over 2 trillion heartbeats, providing early intervention opportunities and improving patient outcomes. This focus not only enhances patient care but also offers potential healthcare cost savings. Q: What are the future growth prospects for Biotricity? A: Dr. Walkus Al Sadiq, CEO, expressed optimism about future growth through the commercialization of products like Biocore Pro, Bioflux, and Biocare. The company is committed to advancing remote monitoring solutions and expanding its geographic footprint, with regulatory approvals in Canada, Saudi Arabia, Argentina, and other markets. Q: How has Biotricity managed to achieve cost efficiencies? A: The CFO explained that cost efficiencies were achieved through strategic transformation of the sales force, focusing on larger accounts and longer sales cycles. Additionally, the use of AI and automation, along with proactive cost management, contributed to positive free cash flows and a path towards profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
25 minutes ago
- Yahoo
Equinox Gold Corp (EQX) Q2 2025 Earnings Call Highlights: Strong Production and Strategic ...
Gold Production: Over 219,000 ounces produced in Q2 2025. Gold Sales: Sold just over 148,000 ounces at an average realized price of $3,200 per ounce. Pro Forma Consolidated Revenue: Approximately $1.33 billion for H1 2025 from 401,000 ounces. Greenstone Mining Rates: Increased 23% in Q2 compared to Q1. Greenstone Processing Rates: Improved 20% over Q1. August Mining Rates: Averaging 200,000 tonnes per day. Best Demonstrated Performance: 227,000 tonnes per day in August. Investment in Critical Spares: Over $25 million to support ramp-up. First Ore to Plant: Scheduled before the end of August 2025. First Gold from Valentine: Anticipated approximately a month after first ore to plant. Sale of Nevada Assets: $115 million. Warning! GuruFocus has detected 10 Warning Signs with EQX. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Equinox Gold Corp (EQX) successfully completed a merger, creating a significant Americas-focused gold producer anchored by two cornerstone Canadian mines, Greenstone and Ballantyne. The company reported strong Q2 2025 production results, delivering over 219,000 ounces of gold, with improvements in mining and processing rates at Greenstone. Equinox Gold Corp (EQX) anticipates increased production, cash flow, and earnings in the coming quarters, driven by contributions from Calibre assets and the commencement of production at Valentine. The company has made significant investments in operational readiness at Valentine, including $25 million in critical spares, with first ore to the plant expected before the end of August. Equinox Gold Corp (EQX) is focused on disciplined capital allocation, operational excellence, and advancing high-quality organic growth, with a strategy to deliver tangible returns to shareholders through margin expansion and potential dividends or share buybacks. Negative Points The grade at Greenstone decreased from 1.06 grams per tonne in Q1 to around 0.9 grams per tonne in Q2, with expectations for gradual improvement over the coming quarters. There are ongoing discussions with a third community at Los Filos, which could impact future operations and agreements. The company is dealing with a tax dispute in Nicaragua and a legal matter in Brazil, which could pose risks to financial outcomes and asset sales. Equinox Gold Corp (EQX) has been undercapitalized in certain areas, such as Los Filos, due to prioritizing capital for Greenstone's ramp-up. The company has not yet provided specific guidance on costs for Valentine, creating uncertainty around future capital expenditures and operating costs. Q & A Highlights Q: The grade at Greenstone came in lower than expected. When should we start seeing improvements, and what measures are being taken to manage and improve grade dilution? A: Darren Hall, CEO: We are seeing improvements in grade, with August grades around a gram per tonne. Improvements are expected as we move more material and improve mining practices. We anticipate quarter-on-quarter improvements, with Q3 grades likely similar to current levels, but with better face positions for effective mining. Q: Do you have all the necessary equipment in place to improve mining rates at Greenstone? A: Darren Hall, CEO: Yes, all required equipment is in place. We are focused on maximizing the value of our committed capital and have seen increased engagement from our partners, ensuring we have the necessary support equipment to improve haul speeds and overall performance. Q: Are there ongoing discussions with the third community at Los Filos, and what is the status of agreements with the communities? A: Darren Hall, CEO: We maintain open dialogue with all stakeholders. We have fully executed agreements with two of the three communities and are working on a two-community plan to exploit Los Filos. We are hopeful for a solution with the third community, Karelia, and will work constructively with all stakeholders. Q: Can you provide an update on the tax dispute in Nicaragua and the legal matter in Aurizona? A: Peter Hardie, CFO: We are confident in a beneficial resolution regarding the Nicaragua tax dispute and have not recorded a provision. The Aurizona legal matter is progressing slowly, typical for Brazil, and we do not expect it to interfere with any asset sales. Q: What are the expected costs for Brazilian operations in the second half of the year? A: Darren Hall, CEO: We are comfortable with our full-year guidance and expect variations quarter-by-quarter. Brazil's operations are seasonally driven, with most production and cash flow in the second half, impacting unit costs. We anticipate better performance as we deploy more capital across assets. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
25 minutes ago
- Yahoo
MediPharm Labs Corp (MEDIF) Q2 2025 Earnings Call Highlights: Strong International Growth ...
Revenue: CAD11.8 million, a 14% increase year over year. International Medical Cannabis Revenue: CAD6.7 million, a 50% increase year over year, accounting for 57% of total revenue. Canadian Medical Cannabis Revenue: CAD3.1 million, a slight decline from Q1 2025. Canadian Adult-Use and Wellness Revenue: CAD1.6 million, a 6% increase year over year and a 19% sequential improvement. Gross Profit: CAD3.3 million, representing 28% of revenue, down from prior periods due to product mix. General and Administrative Expenses: Adjusted for CAD2.2 million proxy contest expense, decreased CAD0.8 million year over year. Adjusted EBITDA: Negative CAD0.6 million for the quarter; year-to-date negative CAD0.4 million, an improvement of CAD0.6 million versus prior year. Cash Balance: CAD10.4 million at the end of Q2, up from CAD8.4 million in Q1, supported by CAD4.5 million from the sale of the Hope facility. Trade and Other Receivables: CAD8 million, with 85% aged 60 days or less. Trade and Other Payables: CAD8.2 million, with up-to-date cannabis excise duties and trade payable obligations. Debt: Virtually no debt, with full ownership of two production facilities valued over CAD15 million. Warning! GuruFocus has detected 2 Warning Signs with MEDIF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points MediPharm Labs Corp (MEDIF) reported a 14% year-over-year increase in revenue, driven by a 50% growth in international medical cannabis sales. The company successfully defended against a costly proxy contest, maintaining shareholder support and alignment with its long-term vision. MediPharm Labs Corp (MEDIF) ended Q2 with CAD10.4 million in cash, up from CAD8.4 million in Q1, despite incurring CAD2.2 million in proxy-related expenses. The company is virtually debt-free and owns its production facilities outright, providing a strong financial position. MediPharm Labs Corp (MEDIF) is actively pursuing international expansion, with significant growth opportunities in markets like Germany, Australia, and the UK. Negative Points The proxy contest incurred significant legal and advisory fees, totaling CAD2.2 million, which temporarily diverted focus from strategic initiatives. Gross profit margin declined to 28% due to product mix challenges, particularly in the international market. Adjusted EBITDA for Q2 was negative CAD0.6 million, reflecting margin dilution from product mix. Canadian medical cannabis revenue declined slightly by CAD0.1 million from Q1 2025. The company faces ongoing challenges in achieving consistent profitability, with a need to balance cost reductions and revenue growth. Q & A Highlights Q: Could you speak to some of the international growth opportunities and specific markets where you see the best near-term opportunities? A: David Pidduck, CEO, highlighted the launch of inhalers in Australia and Europe as exciting opportunities due to their differentiated product and higher margins. He noted challenges in European markets but mentioned new opportunities from dissatisfied customers with existing partners. Growth is also expected in Brazil, with the market growing over 50%, and new European markets like France opening up. Q: What opportunities become available for MediPharm if cannabis is reclassified to Schedule III in the US? A: David Pidduck explained that reclassification could reduce stigma and complexities, allowing market growth. MediPharm, having had an FDA inspection and shipped products for clinical trials in the US, is well-positioned to supply products for research and development. This change could lead to increased research opportunities and commercial benefits. Q: How should we think about achieving more meaningful profitability? Is it simply top-line growth or are there other levers? A: David Pidduck and Greg Hunter, CFO, emphasized a multi-faceted approach, including cost reduction, restructuring, and optimizing product mix for higher margins. They highlighted the importance of revenue growth, particularly through new product launches like inhalers, and potential M&A opportunities to drive profitability. Q: Can you elaborate on the potential impact of M&A on your strategy? A: Greg Hunter noted that M&A is a major pillar of their strategy, citing the successful VIVO acquisition as an example. They are actively pursuing opportunities that offer strategic revenue and cost synergies, aiming to enhance shareholder value and drive significant synergies. Q: What are the key drivers for your international sales growth? A: David Pidduck mentioned that international sales are driven by established presence and partnerships in Germany, the UK, and Australia. The strategic acquisition of VIVO expanded their global footprint, and they continue to leverage GMP licenses to operate confidently in complex regulatory environments. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
